Birgit Grund, Katherine Huppler Hullsiek, and Thomas Murray, of the University of Minnesota, will present:
“Design Considerations from COVID-19 Trials at the University of Minnesota”
Abstract: Beginning in March, Covid-19 upended many on-going clinical trials along with our daily routines, and many investigators across the University sprang into action to design and implement clinical trials evaluating potential therapeutics for Covid-19. Many biostatisticians and statisticians at the University of Minnesota, and the Division of Biostatistics in particular, have played a role in these efforts. Birgit Grund, Katherine Huppler Hullsiek and Thomas Murray will discuss various clinical trials evaluating therapeutics for Covid-19 for which our University and Division has played a key role. Design rationale and challenges will be discussed for trials evaluating hydroxychloroquine as postexposure prophylaxis, neutralizing monoclonal antibody therapies for in-patients, and Losartan as therapy for in- and out-patients.
All are Welcome.